IN8BIO, INC. (INAB)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.34 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$19.44M

Free cash flow

$12.71M

Return on equity

-70.5%

Return on capital

-55.7%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
13 Sep 2023	Graff Jeremy R. Director	Bought	$2.38K	opened
25 Aug 2023	McCall Patrick Chief Financial Officer	Bought	$1.03K	19.0%
24 Aug 2023	Ho William Tai-Wei President and CEO	Bought	$24.99K	1.0%
12 Dec 2022	Kreis Leslie W. Director	Bought	$185.91K	2.1%
12 Dec 2022	Fletcher Aaron G.L. Director	Bought	$185.91K	2.1%
28 Sep 2022	Kreis Leslie W. Director	Bought	$50.54K	0.7%

37out of 100

Profitability 0

Financial strength 70

Growth n/a

Insiders 50

Strongest on financial strength (70), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan